Nanoform Outlicenses Nanoencorafenib and Signs Development and Commercialisation Agreement with A.forall and IMGA
Nanoform Finland Plc | Press Release | October 14, 2025…
Nanoforming Biologics & GLP-1s: From I.V. to Sub Q & Inhaled Delivery
Designing the most patient-centric and effective treatment options are key…
Nanoform Q3 2025 report day set for November 12th, 2025
Nanoform Finland Plc | Press Release | September 26, 2025…
Results of Nanoform Collaborative Study to be Presented at US Drug Delivery & Formulation (DDF) Summit
Nanoform Finland Plc | Press Release | September 11, 2025…